

**MyHealthChecked PLC**  
("MyHealthChecked" or the "Company")

**Confirmation of Capital Reduction**

Further to the announcement made by the Company on 6 December 2022, MyHealthChecked PLC (AIM: MHC), announces today that the reduction of capital (the "**Capital Reduction**"), involving the cancellation of the Deferred Shares, the Share Premium Account and the Capital Redemption Reserve of the Company, has been confirmed by the High Court of Justice of England and Wales (the "**Court**").

The Court order confirming the Capital Reduction, and a statement of capital approved by the Court, is expected to be registered with the Registrar of Companies no later than 31 January 2023.

Full details of the Capital Reduction are set out in the notice of general meeting which was sent to shareholders of the Company on 18 November 2022 (the "**Notice**"). The Notice is also available for inspection on the Company's website.

**For further information contact:**

**MyHealthChecked PLC**

Penny McCormick, Chief Executive Officer

[www.myhealthchecked.com](http://www.myhealthchecked.com)

via Walbrook PR

**SPARK Advisory Partners Limited (NOMAD)**

Neil Baldwin

Tel: +44 (0)20 3368 3550

**Dowgate Capital Limited (Broker)**

David Poutney / Nicholas Chambers

Tel: +44 (0)20 3903 7715

**Walbrook PR Ltd (Media & IR)**

Paul McManus

Tel: +44 (0)20 7933 8780 or [myhealthcheckedplc@walbrookpr.com](mailto:myhealthcheckedplc@walbrookpr.com)

Mob: +44 (0)7980 541 893

**About MyHealthChecked PLC ([www.myhealthcheckedplc.com](http://www.myhealthcheckedplc.com))**

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.

MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests that have been developed following the acquisition of The Genome Store in November 2020. The tests are available online, and in some cases, for over-the-counter purchase.

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

FURNKOBBOBKDFDD